research GPX4 mRNA levels in the PMNs are negatively correlated with autoantibody production, disease activity and lupus alopecia in SLE
Lower GPX4 mRNA levels are linked to higher disease activity and symptoms in lupus patients.
Search
for
Sort by
Research
30 / 1000+ results 
research Clinical and Trichoscopic Patterns of Hair Loss in Systemic Lupus Erythematosus and its Correlation with Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
Hair loss in SLE patients is mostly due to chronic telogen effluvium and is linked to moderate disease activity.
research LP-159 Studying the disease activity and the degree of internal organ damage in systemic lupus erythematosus patients in the Kazakh population
Higher disease activity in systemic lupus erythematosus is strongly linked to more internal organ damage.
research Effect of Alexandrite Laser Hair Removal on the Activity of Systemic Lupus Erythematosus
This study investigated the effect of Alexandrite laser hair removal, which emits red and infrared light, on the activity of Systemic Lupus Erythematosus (SLE) in 20 patients. The participants, mostly female with a mean age of 32.65, underwent six monthly sessions of laser treatment. Key measures of SLE activity, including the SLE disease activity index (SLEDAI-2K) and serum levels of Anti-ds-DNA, C3, and C4, showed no significant changes before and after the treatment. The study concluded that laser hair removal is safe for SLE patients and does not exacerbate the disease.
research Trichoscopic signs in systemic lupus erythematosus: a comparative study with 109 patients and 305 healthy controls
Trichoscopy is useful for diagnosing and monitoring systemic lupus erythematosus, with certain hair and scalp changes indicating more active disease.
research Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates
The document concludes that recognizing and treating cutaneous lupus erythematosus early is crucial for managing the skin and potential systemic symptoms.
research Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage
Choosing the right tools is crucial for accurately measuring lupus activity and damage.
research Fever and rash as initial signs of systemic autoimmune disease. Case Report.
Fever and rash can be early signs of lupus.
research POS0548 ACUTE AND SUBACUTE SKIN MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS ARE ASSOCIATED WITH AN EARLIER RESPONSE TO BELIMUMAB THAN THE CHRONIC PHENOTYPE: PRELIMINARY DATA FROM THE NEW NATION-WIDE COHORT OF BELIMUMAB IN REAL LIFE SETTING STUDY—NEW JOINT AND SKIN (BERLISS-NEJS)
Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.
research AB0442 Real-life experience with belimumab in systemic lupus erythematosus (SLE): control of disease activity and flares in a multicenter cohort
Belimumab effectively controls SLE disease activity and reduces steroid use.
research Cutaneous manifestations and systemic correlation in patients with lupus erythematosus and its subsets: a study of 40 cases
Skin issues like hair loss, rash, and sensitivity to sunlight are key signs of lupus activity.
research The effect of DNMTs and MBPs on hypomethylation in systemic lupus erythematosus
Certain proteins involved in DNA modification may affect the genetic changes in systemic lupus erythematosus and could indicate the disease's activity.
research Lupus eritematoso cutáneo y su asociación con actividad sistémica
More skin lesions in lupus patients may indicate higher disease activity.
research Associated Variables of Myositis in Systemic Lupus Erythematosus: A Cross-Sectional Study
Myositis in lupus patients is linked to skin rash, hair loss, blood issues, and high disease activity.
research Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study
Belimumab reduces disease activity, steroid use, and flares in lupus patients.
research Outcome Measures in Cutaneous Autoimmune Disease: Dermatomyositis and Lupus Erythematosus
The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.
research Anifrolumab treatment improves patient-reported quality of life and decreases disease activity and corticosteroid use in patients with systemic lupus erythematosus: A qualitative study in Denmark
Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.
research Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist
Skin problems are common in lupus patients and should be treated early to prevent worsening.
research Anifrolumab for systemic lupus erythematosus: A clinical study of Japanese patients in Kanazawa University Hospital
Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.
research Skin
Skin problems are common in Lupus patients and can indicate the disease's severity, requiring specific treatments and lifestyle changes.
research Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures
CLASI is a valid tool for assessing skin activity and damage in lupus patients.
research Fibromyalgia, Systemic Lupus Erythematosus (SLE), and Evaluation of SLE Activity
Fibromyalgia slightly more common in SLE patients but doesn't affect SLE activity assessments.
research Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort
Hydroxychloroquine may help delay skin damage in lupus patients.
research SLE and Serum Complement: Causative, Concomitant or Coincidental?
Low serum complement levels in SLE patients don't always match with disease flares; monitoring C3 and C4 is useful, but cell-bound complement products might better indicate disease activity.
research The Spectrum of Health Domains Important to Lupus Patients Early Development of a Disease Activity Patient Reported Outcome.
A new tool helps lupus patients and doctors better track symptoms and quality of life.
research Hair Disorders in Autoimmune Diseases
Hair loss is common in autoimmune diseases and can be an early sign of the condition, often requiring prompt treatment to prevent permanent damage.
research Skin involvement in systemic lupus erythematosus: a review article
Skin problems are common in lupus, often appearing first, with various types and treatments, and careful monitoring is important for diagnosis and management.
research The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances
BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.
research Systemic Lupus Erytomatosa in Pregnancy Accompained by Angioedema
More research is needed to understand and manage angioedema in pregnant women with lupus.
research Nonscarring alopecia in systemic lupus erythematosus: A cross-sectional study with trichoscopic, histopathologic, and immunopathologic analyses
Hair loss in lupus patients indicates higher disease activity.